Table 3.

Nonhematologic toxicities with imatinib in newly diagnosed chronic phase chronic myelogenous leukemia (CML) patients.26 

Adverse EventAll Grades (%)Grades 3/4 (%)
Superficial edema 53.2 0.9 
Nausea 42.5 0.4 
Muscle cramps 35.4 1.1 
Musculoskeletal pain 33.6 2.7 
Rash 31.9 2.0 
Fatigue 30.7 1.1 
Diarrhea 30.3 1.3 
Headache 28.5 0.4 
Joint pain 26.7 2.2 
Abdominal pain 23.4 2.0 
Myalgia 20.9 1.5 
Nasopharyngitis 19.2 
Hemorrhage 18.9 0.7 
Dyspepsia 15.1 
Vomiting 14.7 0.9 
Pharyngolaryngeal pain 14.2 0.2 
Dizziness 13.2 0.5 
Cough 12.5 0.2 
URI 12.5 0.2 
Pyrexia 11.8 0.5 
Weight, increased 11.6 0.7 
Insomnia 11.4 
Depression 8.9 0.5 
Constipation 7.6 0.7 
Rigors 6.9 
Anxiety 6.5 0.2 
Dyspnea 6.5 1.3 
Pruritus 6.5 0.2 
Influenza-like illness 6.4 
Night sweats 6.4 0.2 
Anorexia 4.7 
Sweating, increased 3.3 
Alopecia 2.2 
Adverse EventAll Grades (%)Grades 3/4 (%)
Superficial edema 53.2 0.9 
Nausea 42.5 0.4 
Muscle cramps 35.4 1.1 
Musculoskeletal pain 33.6 2.7 
Rash 31.9 2.0 
Fatigue 30.7 1.1 
Diarrhea 30.3 1.3 
Headache 28.5 0.4 
Joint pain 26.7 2.2 
Abdominal pain 23.4 2.0 
Myalgia 20.9 1.5 
Nasopharyngitis 19.2 
Hemorrhage 18.9 0.7 
Dyspepsia 15.1 
Vomiting 14.7 0.9 
Pharyngolaryngeal pain 14.2 0.2 
Dizziness 13.2 0.5 
Cough 12.5 0.2 
URI 12.5 0.2 
Pyrexia 11.8 0.5 
Weight, increased 11.6 0.7 
Insomnia 11.4 
Depression 8.9 0.5 
Constipation 7.6 0.7 
Rigors 6.9 
Anxiety 6.5 0.2 
Dyspnea 6.5 1.3 
Pruritus 6.5 0.2 
Influenza-like illness 6.4 
Night sweats 6.4 0.2 
Anorexia 4.7 
Sweating, increased 3.3 
Alopecia 2.2 
Close Modal

or Create an Account

Close Modal
Close Modal